import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "first-timer-protocol-conservative-8-week-starter",
  title: "First-Timer Protocol: A Conservative 8-Week Starter",
  description:
    "A methodical guide for researchers beginning their first peptide study — compound selection criteria, conservative dosing frameworks, cycle structure, documentation essentials, and how to build a study design that generates signal rather than noise.",
  category: "Research Protocols",
  readMinutes: 11,
  publishedAt: "2026-07-08",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "The literature on peptide research is dense, often contradictory, and rarely written with the first-time researcher in mind. Most published protocols assume an existing foundation: familiarity with compound handling, established baseline biomarkers, and the institutional or personal infrastructure to run a clean study. When that foundation is absent, what looks like a straightforward 8-week protocol can generate data that cannot be interpreted — or worse, outcomes that are difficult to attribute to the intervention itself.",
    },
    {
      type: "paragraph",
      text: "This guide is written for the researcher beginning their first peptide study. The approach is deliberately conservative: one compound, well-characterized in the literature, with a dosing range defined by the most replicated published protocols, run for eight weeks with structured documentation. The goal is not to maximize observed effect — it is to run a clean study that generates interpretable signal.",
    },
    {
      type: "heading",
      text: "Compound Selection: One Variable",
    },
    {
      type: "paragraph",
      text: "The most common error in first studies is selecting multiple compounds simultaneously. Researchers who have read extensively about peptide synergy often want to immediately test stacks: BPC-157 plus TB-500, or CJC-1295 plus Ipamorelin. The motivation is understandable — combination effects are genuinely interesting, and the single-compound data may feel insufficient to justify the overhead of a study.",
    },
    {
      type: "paragraph",
      text: "The problem is interpretability. If you administer two compounds and observe an effect, you cannot attribute causality to either. If you observe no effect, you cannot determine whether one compound was inactive or whether the two were antagonistic. A two-compound first study doubles your cost and halves your information.",
    },
    {
      type: "paragraph",
      text: "Start with one compound. The candidates below are recommended based on three criteria: well-characterized mechanism in published literature, high replicated reproducibility across multiple independent labs, and a clearly defined dosing range with established safety data in animal models.",
    },
    {
      type: "subheading",
      text: "Recommended First-Study Candidates",
    },
    {
      type: "list",
      items: [
        "BPC-157 — the most extensively documented repair peptide in preclinical research. Stable in lyophilized form, water-soluble, broad tissue distribution. Published dosing range: 10–15 mcg/kg in rodent models, typically 2–4 mcg/kg in higher mammal analogs. Well-characterized in GI, musculoskeletal, and neurological endpoints.",
        "Ipamorelin — highly selective GH secretagogue with minimal cortisol or prolactin elevation compared to GHRP-2 or GHRP-6. Published dosing range: 200–300 mcg per injection, 1–2x daily. Predictable pulsatile GH response makes it one of the cleaner GH research tools available.",
        "TB-500 (Thymosin Beta-4 synthetic fragment) — data-rich tissue repair compound with strong musculoskeletal and vascular research base. Excellent for researchers interested in actin dynamics and wound healing endpoints. Typically 2–5 mg 2x weekly in published protocols.",
        "GHK-Cu — well-tolerated copper peptide with extensive literature on skin, connective tissue, and wound healing. Good entry point for researchers interested in inflammatory resolution and ECM remodeling. Dosing range is context-dependent but well-characterized for topical and injectable use.",
      ],
    },
    {
      type: "paragraph",
      text: "All four compounds have published literature exceeding 50 peer-reviewed studies. That literature base is the asset — not just for informing your study design, but for contextualizing your outcomes against a benchmark.",
    },
    {
      type: "heading",
      text: "Establishing Baseline Before Week 1",
    },
    {
      type: "paragraph",
      text: "Baseline measurement is not optional. It is the reference against which every observation in your study will be interpreted. Without it, you cannot determine effect direction, let alone magnitude.",
    },
    {
      type: "paragraph",
      text: "The specific baseline measurements you need depend on your primary research endpoint. The list below covers the most common domains across the four recommended starter compounds:",
    },
    {
      type: "subheading",
      text: "Repair and Tissue Endpoints (BPC-157, TB-500, GHK-Cu)",
    },
    {
      type: "list",
      items: [
        "Inflammatory markers: CRP, IL-6, TNF-alpha — provides baseline systemic inflammation against which repair effects can be measured",
        "Tissue-specific functional assessments: range of motion metrics, grip strength, relevant mobility markers depending on target tissue",
        "Imaging documentation if structural changes are an endpoint — baseline photographs for wound healing, ultrasound for tendon studies",
        "Basic metabolic panel: ensures compound is being studied in the context of known metabolic status",
      ],
    },
    {
      type: "subheading",
      text: "GH Axis Endpoints (Ipamorelin, CJC-1295)",
    },
    {
      type: "list",
      items: [
        "IGF-1 — primary downstream mediator of GH effect; the most practical single marker for GH axis activation",
        "Fasting glucose and insulin — GH secretagogues can affect insulin sensitivity; document baseline before any intervention",
        "Body composition metrics if relevant — lean mass and fat mass measurements establish the structural baseline",
        "Sleep quality documentation — GH secretagogues affect pulsatile GH release during slow-wave sleep; subjective and objective sleep data adds interpretive value",
      ],
    },
    {
      type: "paragraph",
      text: "Take baseline measurements across at least two separate readings, ideally a week apart, before beginning dosing. Single-point baselines are vulnerable to day-of variance. Two-point baselines allow you to establish whether measurements are stable or drifting before the compound enters the picture.",
    },
    {
      type: "heading",
      text: "The 8-Week Protocol Structure",
    },
    {
      type: "paragraph",
      text: "Eight weeks is long enough to capture effects that require compound accumulation or downstream biological responses — but not so long that confounding variables (training changes, dietary shifts, seasonal factors) begin to dominate. It is the most commonly used window in the published peptide protocols for the four compounds above.",
    },
    {
      type: "subheading",
      text: "Weeks 1–2: Dose Ramp",
    },
    {
      type: "paragraph",
      text: "Begin at 50–60% of your target dose in weeks one and two. This is not strictly necessary from a biological standpoint — the compounds above do not have documented tolerance-requiring dose titration — but it gives you time to confirm your reconstitution volumes are accurate, your administration technique is consistent, and your documentation system is working before you are at full study dose.",
    },
    {
      type: "paragraph",
      text: "Use the ramp period to establish your injection timing and site rotation protocol. Subcutaneous injection is the standard route for most of these compounds in published protocols. Rotate injection sites across the same anatomical region to avoid local tissue accumulation effects that would confound systemic interpretations.",
    },
    {
      type: "subheading",
      text: "Weeks 3–6: Core Dosing Window",
    },
    {
      type: "paragraph",
      text: "This is your primary data collection window. Full dose, consistent timing, structured documentation. The specific dosing schedules by compound:",
    },
    {
      type: "list",
      items: [
        "BPC-157: 250–500 mcg/day, subcutaneous, split into 1–2 injections. Daily dosing is most replicated in the literature. Some protocols use 5-on/2-off cycling — either approach is defensible, but consistency within your study is mandatory.",
        "Ipamorelin: 200–300 mcg per injection, 1–2x daily. Pre-sleep injection captures natural GH pulse window. If two injections, space by 8+ hours. Must be injected on an empty stomach (2 hours post-meal minimum) to avoid blunting GH pulse.",
        "TB-500: 2 mg twice weekly, subcutaneous. Less frequent dosing than BPC-157; some researchers use a 2 mg/week maintenance schedule after an initial 4 mg/week loading month. Keep dosing schedule consistent throughout.",
        "GHK-Cu: 1–2 mg per injection, 2–3x weekly. Some protocols use daily micro-dosing at 0.5 mg; published literature supports either approach depending on endpoint.",
      ],
    },
    {
      type: "subheading",
      text: "Week 7: Taper or Hold",
    },
    {
      type: "paragraph",
      text: "Week 7 is an optional taper week: either continue full dose through to end of week 8, or reduce to 50% dose and take a mid-point biomarker measurement. The mid-point measurement — if your baseline required blood draws — gives you an in-protocol signal check. It is particularly valuable for IGF-1 measurement in GH axis studies, where you expect to see elevation by week 6–7.",
    },
    {
      type: "subheading",
      text: "Week 8: Final Measurement Window",
    },
    {
      type: "paragraph",
      text: "Final measurements should mirror baseline: same assay panels, same timing relative to last injection, same fasting state where relevant. The temporal relationship between last dose and final blood draw matters: for GH secretagogues, measuring IGF-1 within 12 hours of last injection versus 72 hours will produce different readings. Your measurement window should be pre-specified and held constant.",
    },
    {
      type: "heading",
      text: "Documentation: What to Record and Why",
    },
    {
      type: "paragraph",
      text: "Documentation is where most first-time studies fail — not in the dosing phase, but in the recording phase. The goal of documentation is to create a reconstruction path: if you need to explain or defend any observation 6 months later, everything required to do so should be in your records.",
    },
    {
      type: "subheading",
      text: "Daily Log (Minimal Viable Version)",
    },
    {
      type: "list",
      items: [
        "Date, time of injection, injection site, dose administered",
        "Lot number and vial ID of compound used (critical for identifying batch-level variance)",
        "Any acute responses within 4 hours of injection — including absence of response",
        "Subjective daily rating across your primary endpoints (1–10 scale, consistent criteria)",
      ],
    },
    {
      type: "subheading",
      text: "Weekly Log",
    },
    {
      type: "list",
      items: [
        "Objective measurements for your primary endpoints",
        "Any protocol deviations (missed dose, timing shift, dose error) — do not omit these; document and note them",
        "Storage conditions check for remaining compound",
        "Weight and basic health status if metabolic endpoints are involved",
      ],
    },
    {
      type: "paragraph",
      text: "The lot number documentation deserves specific emphasis. Peptide research suffers from batch-to-batch variance that is rarely acknowledged in self-published protocols. If you source consistently from a supplier with verified HPLC and mass spec data on every batch, you can rule out purity variance as a confound. If you do not, you cannot.",
    },
    {
      type: "heading",
      text: "Post-Cycle Assessment: The Off-Period",
    },
    {
      type: "paragraph",
      text: "The 4-week period following your 8-week study is as scientifically valuable as the study itself, and is rarely discussed. Peptide effects do not terminate at the final injection — many biological responses, particularly in repair and GH axis research, continue to evolve during the washout period.",
    },
    {
      type: "paragraph",
      text: "Take a final biomarker panel at 2 weeks post-final-dose and again at 4 weeks. This gives you a washout curve that tells you: how long effects persist, whether there is a rebound after GH axis stimulation ends, and whether any compound-period gains are maintained without ongoing administration.",
    },
    {
      type: "paragraph",
      text: "For repair compounds like BPC-157 and TB-500, the 4-week post-cycle window often shows continued structural remodeling as initiated by the compound — tissue does not stop healing at the final injection. For GH secretagogues, IGF-1 typically returns toward baseline within 4–6 weeks of cessation, giving you a clean washout window before any second study.",
    },
    {
      type: "heading",
      text: "Common Design Errors to Avoid",
    },
    {
      type: "list",
      items: [
        "Starting without documented baseline measurements — any result is uninterpretable without a pre-intervention reference point",
        "Changing diet or training significantly during the study — these are major confounds for any compound with metabolic or repair endpoints",
        "Using unverified compounds without COA data — purity variance makes your results unattributable to the compound",
        "Inconsistent injection timing — especially problematic for GH secretagogues where timing relative to meals and sleep is pharmacologically significant",
        "Skipping the post-cycle assessment — you are missing half the biological story",
        "Adding a second compound mid-study if initial response looks interesting — this collapses your ability to interpret the first compound's effect",
      ],
    },
    {
      type: "heading",
      text: "Compound Handling Essentials",
    },
    {
      type: "paragraph",
      text: "First-study failure often occurs not in protocol design but in compound handling. Lyophilized peptides require specific reconstitution and storage conditions to maintain activity throughout an 8-week study.",
    },
    {
      type: "list",
      items: [
        "Reconstitute with bacteriostatic water (BAC water) for multi-use vials — not sterile water, which does not contain the preservative necessary for extended vial life",
        "Inject BAC water slowly down the vial wall; do not vortex or shake — swirl gently to dissolve",
        "Reconstituted peptides are stable 4–6 weeks refrigerated at 2–8°C; lyophilized (unreconstituted) vials can be frozen for extended storage",
        "Pull reconstituted vials from refrigerator 15–20 minutes before injection to allow temperature equilibration — cold-injection SC discomfort is avoidable",
        "Calculate your total study dose before reconstituting — reconstitute in volumes that let you draw clean, consistent doses without excessive measurement error",
      ],
    },
    {
      type: "divider",
    },
    {
      type: "callout",
      text: "All compounds discussed in this article are sold for research purposes only. This content is intended for researchers operating in academic, institutional, or compliant research contexts. It does not constitute medical advice and is not applicable to human clinical use. Consult applicable regulations in your jurisdiction before beginning any peptide research protocol.",
    },
  ],
};
